drugset
drugset / Trial / NCT04221204

A Monotherapy in Subjects With Advanced Solid Tumors

NCT04221204 ↗

Phase 1 Active not recruiting 42 enrolled 3D Medicines (Beijing) Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors

Timeline

Start
2019-09-01
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 3D185 Unknown 50 mg Oral
Subject 3D185 Unknown 100 mg Oral
Subject 3D185 Unknown 150 mg Oral
Subject 3D185 Unknown 200 mg Oral
Subject 3D185 Unknown 250 mg Oral
Subject 3D185 Unknown 300 mg Oral

Indications

cancer